Sign in →

Test Code MSAES Myositis Specific Antibody Evaluation, Serum


Ordering Guidance


This test is appropriate for patients presenting with proximal muscle weakness, elevated muscle enzymes (eg, creatine kinase), and/or suggestive cutaneous features (eg, heliotrope rash, Gottron’s papules) consistent with myositis and related disorders. This test can assist in classifying IIM subtypes (eg, dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, or inclusion body myositis. It may be useful in distinguishing idiopathic inflammatory myopathy from overlapping connective tissue diseases (CTDs). For patients with suspicion of overlap syndromes with CTDs additional myositis-associated antibody testing may be warranted beyond this panel.



Additional Testing Requirements


In patients with atypical or non-classical presentations testing for some myositis associated antibodies may be considered including anti-U1-snRNP, PM/Scl, Ro52 or Ro60.



Necessary Information


Provide the following information:

-Relevant clinical information

-Ordering provider name, phone number, mailing address, and e-mail address



Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 2.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Forms

If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.

Useful For

Accurately diagnosing, classifying, and managing idiopathic inflammatory myopathies (IIM) by identifying subtype-specific biomarkers that guide prognosis and treatment

 

Enabling early detection of IIM, particularly in atypical or severe cases, and reducing diagnostic uncertainty for personalized care

Profile Information

Test ID Reporting Name Available Separately Always Performed
EJS EJ Ab, S No Yes
HMGCR HMG-CoA Reductase Ab, S Yes Yes
JO1 Jo 1 Ab, IgG, S Yes Yes
MDA5S MDA5 Ab, S No Yes
MI2S Mi2 Ab, S No Yes
MYSI Myositis Specific Ab Interp, S No Yes
NXP2S NXP2 Ab, S No Yes
OJS OJ Ab, S No Yes
PL12S PL12 Ab, S No Yes
PL7S PL7 Ab, S No Yes
SAE1S SAE1 Ab, S No Yes
SRPIS SRP IFA Screen, S No Yes
TIFGS TIF1G Ab, S No Yes

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
SRPBS SRP Immunoblot, S No No
SRPTS SRP IFA Titer, S No No

Testing Algorithm

If the indirect immunofluorescence assay (IFA) pattern suggests signal recognition particle (SRP) antibody, then the SRP IFA titer and SRP54 immunoblot will be performed at an additional charge.

Method Name

EJS, MDA5S, MI2S, NXP2S, OJS, PL12S, PL7S, SAE1S, TIFGS: Bead-Based Multi-Analyte Immunoassay

JO1: Multiplex Flow Immunoassay (MFI)

SRPIS, SRPTS: Indirect Immunofluorescence Assay (IFA)

HMGCR: Chemiluminescence Immunoassay (CIA)

SRPBS: Immunoblot (IB)

MYSI: Technical Interpretation

Reporting Name

Myositis Specific Ab Eval, S

Specimen Type

Serum

Specimen Minimum Volume

1.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Heat-Treated Reject

Clinical Information

Myositis-specific antibody (MSA) testing plays a crucial role in diagnosing, classifying, and managing idiopathic inflammatory myopathies (IIM). These antibodies serve as biomarkers to identify specific subtypes of IIM, assess disease activity, and predict prognosis. Testing is particularly indicated in patients with suspected IIM who present with proximal muscle weakness, elevated muscle enzymes (eg, creatine kinase), and characteristic cutaneous features such as heliotrope rash or Gottron’s papules. MSAs are also essential for differentiating IIM subtypes, including dermatomyositis, polymyositis, inclusion body myositis, necrotizing autoimmune myopathy, and anti-synthetase syndrome. In cases of non-classical or atypical presentations, such as clinically amyopathic dermatomyositis or overlap syndromes with connective tissue diseases (eg, systemic sclerosis, Sjogren syndrome, or lupus), MSA testing can help clarify the diagnosis.

 

Additionally, MSAs are highly relevant in patients with interstitial lung disease (ILD), particularly when it may be associated with myositis (eg, autoantibodies to Jo-1, threonyl-tRNA synthetase [PL7], alanyl-tRNA synthetase [PL12], or melanoma differentiation-associated protein 5 [MDA5]). They also aid in identifying cancer-associated myositis, especially in patients with dermatomyositis or suspected malignancy (eg, autoantibodies to transcriptional intermediary factor 1 gamma [TIF1g] or nuclear matrix protein 2 [NXP2]). For patients with unexplained severe muscle weakness or necrosis on biopsy, such as those with necrotizing autoimmune myopathy, MSAs like anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and anti-signal recognition particle (SRP) are critical for diagnosis and management. Testing is further recommended when a delay in diagnosis or diagnostic uncertainty exists, especially if initial investigations, such as biopsies, are inconclusive.

 

Clinically, MSAs enable precise phenotyping and stratification of IIM subtypes, providing insights into associated extra muscular disease activity, disease prognosis, and therapeutic responses. For example, anti-MDA5 positivity is linked with rapidly progressive ILD, while anti-TIF1g indicates a high risk of cancer in dermatomyositis. Antibodies such as anti-Jo-1 may guide treatment, as they predict better responsiveness to steroids. However, accurate interpretation of results requires alignment with the patient’s clinical presentation to avoid false positives or negatives, especially given variability in testing methods across laboratories. Early and accurate testing ensures prompt diagnosis and tailored management, particularly in rapidly progressive cases like anti-MDA5-associated ILD, emphasizing the importance of MSAs in advancing personalized care in IIM.

Reference Values

Test ID

Reporting Name

Methodology*

Reference Value

MYSI

Myositis Specific Ab Interp, S

Technical interpretation

Interpretive report

EJS

EJ Ab, S

PMAT

Negative

HMGCR

HMG-CoA Reductase Ab, S

CIA

<20.0

JO1

Jo 1 Ab, IgG, S

MFI

<1.0 U

MDA5S

MDA5 Ab, S

PMAT

Negative

MI2S

Mi2 Ab, S

PMAT

Negative

NXP2S

NXP2 Ab, S

PMAT

Negative

OJS

OJ Ab, S

PMAT

Negative

PL12S

PL12 Ab, S

PMAT

Negative

PL7S

PL7 Ab, S

PMAT

Negative

SAE1S

SAE1 Ab, S

PMAT

Negative

SRPIS

SRP IFA Screen, S

IFA

Negative

TIFGS

TIF1G Ab, S

PMAT

Negative

 

*Methodology abbreviations:

Bead-based multi-analyte immunoassay (PMAT)

Multiplex flow immunoassay (MFI)

Indirect immunofluorescence assay (IFA)

Chemiluminescence immunoassay (CIA)

Immunoblot (IB)

Interpretation

The presence of a myositis-specific antibody provides supportive evidence of an idiopathic inflammatory myopathy and/or related disorder. However, these results must be interpretated in the appropriate clinical context. A negative result does not exclude the possibility of an idiopathic inflammatory myopathy.

Cautions

It is important to note the while myositis-specific antibody testing provides valuable information, it should be used in conjunction with clinical evaluation, physical examination and other diagnostic tests to arrive at a comprehensive and accurate diagnosis.

 

In routine clinical testing, antibody testing for myositis specific antibodies maybe performed using a variety of solid-phase immunoassays such as the enzyme-linked immunosorbent assay, line immunoassay, chemiluminescence immunoassay, fluorescent enzyme immunoassay, and various radioimmunoprecipitation assays. The performance characteristics of these assays for the detection of each myositis-specific antibody have not been extensively investigated to establish comparability.

Clinical Reference

1. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66(10):1345-1349

2. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support the diagnosis of myositis. J Intern Med. 2016;280(1):8-23

Method Description

Bead-based Multi-analyte Technology:

The assay uses a multi-analyte bead-based immunoassay methodology (utilizing particle-based multi-analyte technology), where antigens are bound to paramagnetic beads. These beads are incubated with patient serum samples, allowing any specific IgG antibodies present to bind to the antigens. Unbound antibodies are washed away, and a secondary antibody conjugated to a detectable fluorescent label is added, forming a complex with the bound IgG. The intensity of the fluorescent signal produced is proportional to the concentration of specific IgG antibodies in the serum, which is then measured and interpreted qualitatively.(Unpublished Mayo method)

 

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase:

IgG antibodies to 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) are detected by a chemiluminescent assay using the Inova BIO-FLASH instrument. HMGCR antigen is coated on to paramagnetic beads, which are stored in the reagent cartridge lyophilized. When the assay cartridge is ready to be used for the first time, a buffer solution is added to the tube containing the beads, and the beads are resuspended with the buffer. The reagent cartridge is then loaded onto the BIO-FLASH instrument. A patient serum sample is diluted 1:17 by the instrument in a disposable plastic cuvette. An aliquot of the diluted patient serum, HMGCR-coupled beads, and assay buffer are combined into a second cuvette and mixed. This cuvette is incubated at 37° C. The beads are then magnetized and washed several times. Isoluminol conjugated anti-human IgG antibody is then added to the cuvette, and incubated at 37° C. Again, the beads are magnetized and washed repeatedly. The isoluminol conjugate produces a luminescent reaction when "trigger" reagents are added to the cuvette. The light produced from this reaction is measured as relative light units (RLU) by the BIO-FLASH optical system. RLU values are proportional to the amount of bound isoluminol conjugate, which in turn is proportional to the amount of anti-HMGCR antibodies bound to the antigen on the beads. The QUANTA Flash HMGCR assay utilizes a predefined lot specific master curve that is uploaded into the instrument through the reagent cartridge barcode. Based on the results obtained by running two calibrators, an instrument specific working curve is created, which is used by the software to calculate chemiluminescent units from the RLU value obtained for each sample.(Package insert: QUANTA Flash HMGCR 701333. Inova Diagnostics, Inc; v04, 09/2018)

 

Signal Recognition Protein Indirect Immunofluorescence Assay:

The patient's sample is tested by a standardized indirect immunofluorescence assay that uses composite frozen sections of mouse cerebellum, kidney, and gut tissues. After incubation with patient sample and washing, fluorescein-conjugated goat antihuman IgG is applied. Signal recognition protein (SRP)-specific autoantibodies are identified by their characteristic fluorescence staining patterns. Samples that are scored positive are titrated to an endpoint. Interference by coexisting non-neuron-specific autoantibodies is eliminated or lessened by serologic absorption. This method does not distinguish between antibodies against different SRP proteins.(Package insert: EUROLINE Autoimmune Inflammatory Myopathies 16 Ag (IgG) test instruction. EUROIMMUN Medizinische Labordiagnostika AG, 03/2018)

 

SRP Immunoblot:

The assay is performed using the EUROBlotOne instrument. All reagents required are supplied in the kit. Samples are diluted 1:100 (15 mcL in 1.5 mL sample buffer) and added to the strips placed in incubation trays. The sample and test strips are incubated for 30 minutes at room temperature. Unbound antibodies are removed from trays by washing steps using wash buffer. Bound patient IgG antibodies are detected by adding antihuman-IgG antibodies coupled to horse radish peroxidase followed by incubation at room temperature for 30 minutes. The strips are washed again to remove excess antihuman-IgG antibodies. The substrate is added for 10 minutes (room temperature), and the reaction is subsequently stopped. The strip is scanned, and band intensities are digitized. The digital image is converted to band signal intensities by the EUROLineScan software, which are normalized to an internal standard. Bands corresponding to SRP with signal intensities of 15 U (arbitrary) or greater are reported as positive. The SRP antigen used is recombinant SRP 54. Positive immunoblot results confirm that a patient's serum contains antibodies directed against the SRP 54 subunit. Negative immunoblot results do exclude the presence of SRP antibodies.(Package insert: EUROLINE Autoimmune Inflammatory Myopathies 16 Ag (IgG) test instruction. EUROIMMUN Medizinische Labordiagnostika AG; 03/2018)

 

JO 1 Multiplex Flow Immunoassay:

Recombinant Jo 1 antigen is coupled covalently to polystyrene microspheres, which are impregnated with fluorescent dyes to create a unique fluorescent signature. Jo 1 antibodies, if present in diluted serum, bind to the Jo 1 antigen on the microspheres. The microspheres are washed to remove extraneous serum proteins. Phycoerythrin (PE)-conjugated antihuman IgG antibody is then added to detect IgG anti-Jo 1 bound to the microspheres. The microspheres are washed to remove unbound conjugate, and bound conjugate is detected by laser photometry. A primary laser reveals the fluorescent signature of each microsphere to distinguish it from microspheres that are labeled with other antigens, and a secondary laser reveals the level of PE fluorescence associated with each microsphere. Results are calculated by comparing the median fluorescence response for Jo 1 microspheres to a 4-point calibration curve.(Package insert: Bioplex 2200 ANA Screen. Bio-Rad Laboratories, 02/2019)

 

Interpretation:

An interpretation based on test results is generated by the laboratory information system.

Day(s) Performed

Varies

Report Available

3 to 7 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86255 x10

82397

86235

84182-SRPBS (if appropriate)

86256-SRPTS (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MSAES Myositis Specific Ab Eval, S In Process

 

Result ID Test Result Name Result LOINC Value
607414 HMG-CoA Reductase Ab, S 93493-5
622115 Myositis Specific Ab Interp, S 69048-7
622112 TIF1G Ab, S In Process
622114 SAE1 Ab, S In Process
622108 PL7 Ab, S 33772-5
622109 PL12 Ab, S 33771-7
622074 OJ Ab, S 45152-6
622110 NXP2 Ab, S In Process
622113 Mi2 Ab, S 18485-3
622111 MDA5 Ab, S In Process
621604 EJ Ab, S 45149-2
JO1 Jo 1 Ab, IgG, S 33571-1
603540 SRP IFA Screen, S 97562-3

NY State Approved

Yes